Abstract
The opinions of patients with allergic skin diseases often determine their attitudes to treatment. However, little is known about the viewpoints of patients and their concerns regarding their conditions. This novel study is the first to compare relationships between the opinions of patients and their concerns regarding the severity of atopic dermatitis or chronic spontaneous urticaria and the presence or absence of biologics. We also compared and clarified the characteristics of these diseases using a questionnaire that was completed by 359 patients treated at university and city hospitals, as well as dermatology clinics. Covariance analysis was performed to compare both diseases with different backgrounds. Patients with adult atopic dermatitis were more likely than those with chronic idiopathic urticaria to believe that treatment must be continued and that the disease will not spontaneously improve. Patients with severe or poorly controlled atopic dermatitis or chronic spontaneous urticaria often had psychosomatic symptoms and also believed that the disease required continued treatment. Social factors related to wait times and medication were not associated with disease severity. Patients receiving treatment had significantly less anxiety associated with biologics than those who did not receive treatment. Patients with atopic dermatitis had higher physical and mental burden than those with chronic spontaneous urticaria. Therefore, effective treatments must be prescribed. Consideration of these disease-specific characteristics regarding the opinions and concerns of patients can improve patient satisfaction and compliance with treatment, which results in favorable outcomes.
Introduction
The views that patients have of an illness is a phenomenon consisting of multiple dimensions that overlap but are independent of each other [1]. Atopic dermatitis (AD) is a skin allergy with a high disease burden that decreases the quality of life of patients. In addition, doctors and patients differently rate treatment goals and satisfaction with treatment [2, 3]. Urticaria is a common skin disorder. It mostly comprises acute and chronic spontaneous types that cause wheals to develop over the course of a day or for ≥6 weeks, respectively [4]. Compliance with treatment of chronic spontaneous urticaria (CSU) is poor when symptoms improve [4], which might be owing to the attitudes of patients [4]. If patients are not eager to treat the disease, they might not be optimistic about or compliant with treatment. In addition, how AD and CSU are perceived by doctors and patients differ. Previous interview viewpoints have shown that patients believe the disease “is like the bad guy in a movie that refuses to die” [5].
This report describes the results of a survey of patients with AD and CSU regarding medication compliance using the Physician Global Assessment (PGA), itch numerical rating scale (NRS), and opinions and concerns that patients have about the disease. The effects of patient-reported outcomes, treatment methods, and other factors on patient perceptions of the disease were analyzed. Insights and concerns regarding each disease were also compared.
Methods
Patients
This study included 359 patients who were diagnosed with AD or CSU according to the respective guidelines for these diseases [6, 7]. All patients were treated at the Department of Dermatology of Shimane University Hospital, Masuda Red-Cross Hospital, Kyushu University Hospital, Sapporo Medical University Hospital, Sumikawa Dermatology and Allergy Clinic, Kobe University Hospital, and Kyoto Prefectural University of Medicine University Hospital between May 2020 and February 2022. Patient data were anonymized before analysis.
Inclusion and exclusion criteria
The inclusion criteria comprised age ≥15 years, diagnosis of AD or CSU, and ability to respond to the questionnaire. The exclusion criteria comprised age <15 years and unable to respond to the questionnaire.
Questionnaire
Patients completed a questionnaire developed for this study (Table 1) and described their diagnosis and disease severity using the PGA, which provides a composite score on a scale of 0–4. The questionnaire was self-administered and included multiple-choice items regarding age, sex, occupation, annual income, educational level, lifestyle, and disease duration. A section based on the Patient-Oriented Eczema Measure (POEM) was also included [6, 8]. Mild, moderate, and severe AD was defined by POEM scores of <7, 8–16, and >16, respectively. Symptom control was assessed using the self-administered urticaria control test (UCT) [7, 9]. Patients with CSU who had UCT scores of <12 and ≥12 were, respectively, classified as having poorly and well-controlled disease. Patients described their current medications, willingness to undergo treatment, and satisfaction with the treatment plan using an 11-point scale. Their opinions and concerns regarding their disease were described using a 5-point scale.
TABLE 1
| No. | Sub no. | Item | Possible responses |
|---|---|---|---|
| 1a | 1 | Disease name | 1. Atopic dermatitis |
| 2. Chronic spontaneous urticaria | |||
| 2 | Severity (Physician Global Assessment) | 1. Clear or almost clear | |
| 2. Mild | |||
| 3. Moderate | |||
| 4. Severe | |||
| 2 | Age | Years | |
| 3 | Sex | Male or Female | |
| 4 | Current salary | Yen | |
| 5 | How long have you had your current disease? | Years | |
| 6 | What is your level of schooling? | Graduate school, college, community college, vocational school, high school, middle school cyclosporine oral steroids topical steroids antihistamine topical tacrolimus moisturizer biologics (Xolair, Dupixent) others | |
| 7 | List your current medications (Multiple answers allowed) | ||
| 8 | 1 | If you have atopic dermatitis, please answer the POEM questionnaire | Score |
| 2 | If you have chronic idiopathic urticaria, please answer the UCT questionnaire | Score | |
| 9 | 1 | Itch numerical rating scale | Score |
| Please select one number that best describes your itchiness in the last 24 h | |||
| 11-point evaluation | |||
| 0 1 2 3 4 5 6 7 8 9 10 | |||
| No itchiness Highest possible itchiness | |||
| 10 | What is your viewpoint of your disease? | ||
| 1 | Requires continued treatment | 1 Strongly disagree | |
| 2 | Cannot be healed | 2 Disagree | |
| 3 | It is like the bad guy in a movie who does not die | 3 Neither agree nor disagree | |
| 4 | Related to mental state | 4 Agree | |
| 5 | Difficult disease | 5 Strongly agree | |
| 6 | Improves naturally | ||
| 7 | Improves with treatment | ||
| 11 | How much do each of the following things bother you in relation to your illness? | ||
| 1 | Itchiness | Five-level evaluation | |
| 2 | Pain | 1 Not at all troublesome | |
| 3 | Multiple symptoms | 2 Not troublesome | |
| 4 | Willingness to seek treatment | 3 Neutral | |
| 5 | Not improving | 4 Troublesome | |
| 6 | Chronic exacerbation/remission cycle | 5 Very troublesome | |
| 7 | Few patients have the same disease | ||
| 8 | Long waiting time required to see a doctor | ||
| 9 | Expensive to treat | ||
| 10 | Unknown exacerbating factors | ||
| 11 | Understanding my symptoms | ||
| 12 | Mental illness | ||
| 13 | Restriction of daily life due to illness | ||
| 14 | Not knowing how long the treatment will last | ||
| 15 | Physician fails to indicate treatment goals | ||
| 16 | Not knowing the treatment goals | ||
| 17 | Concerns regarding my appearance | ||
| 18 | Not being able to confide in my doctor | ||
| 19 | Not knowing how to apply ointments | ||
| 20 | Concerns regarding the use of topical steroids | ||
| 21 | Concerns regarding the use of antihistamines (itch relievers) | ||
| 22 | Anxiety regarding the use of oral cyclosporine | ||
| 23 | Anxiety regarding the use of biologics (Xolair or Dupixent) | ||
| 24 | Continuing treatment without forgetting | ||
| 12 | How motivated are you to seek treatment for your illness? | Scale number 10 is good | |
| 11-point evaluation | |||
| 0 1 2 3 4 5 6 7 8 9 10 | |||
| Not at all Very motivated | |||
| 13 | Do you think your illness will be cured? | Scale number 10 is good | |
| 11-point evaluation | |||
| 0 1 2 3 4 5 6 7 8 9 10 | |||
| No Yes | |||
| 14 | Please provide us with any feedback you may have about this questionnaire (free response) | Free response |
Questionnaire items.
This item was completed by a physician.
Statistical analysis
All data were statistically analyzed using R 4.0.3 software [10]. Statistical significance was set at p < 0.05. The characteristics of patients with AD and CSU were compared. Continuous variables are presented as means and standard deviations or as medians and interquartile ranges. Categorical variables are presented as numbers and ratios (%).
The basic characteristics of each disease were compared using Mann–Whitney U tests. The responses of the patients to POEM were compared using Kruskal–Wallis tests. The UCT results and differences between biologic treatments were compared using Wilcoxon rank sum tests.
As disease severity significantly impacts the opinions and concerns of patients, we adjusted the data for severity, age, and sex and used analyses of covariance (ANCOVA) for comparisons.
Results
Analysis of patients
This study included 359 patients, of which 202 had AD (113 men and 89 women; mean age: 39.3 ± 13.6 years) and 157 had CSU (51 men and 106 women; mean age: 48.5 ± 17.0 years) (Table 2). The PGA scores were higher in patients with AD than with CSU (p < 0.001, Mann–Whitney U test) and significantly correlated with POEM (p < 0.001, Kruskal–Wallis test) and UCT (p < 0.001, Wilcoxon rank sum test) scores (Tables 2, 3). The motivation to undergo treatment and ratio of patients who believed that the disease would be cured was higher among those with CSU than with AD (p < 0.001 Mann–Whitney U test).
TABLE 2
| Atopic dermatitis | Chronic spontaneous urticaria | |
|---|---|---|
| Total patients, n (male, female) | 202 (m 113, f, 89) | 157 (m, 51, f, 106) |
| Age (y; means ± SD) | 39.3 ± 13.6 | 48.5 ± 17.0 |
| Median disease duration, y (IQR) | 26.5 (13–37) | 4 (1–10) |
| Median patient-reported outcomes y (IQR) | POEM 9 (4–17) | UCT 12 (9–16) |
| PGA* | ||
| 0 clear or almost clear | 11 (6%) | 52 (33%) |
| 1: Mild | 70 (35%) | 54 (34%) |
| 2: Moderate | 67 (33%) | 29 (19%) |
| 3: Severe | 23 (11%) | 10 (6%) |
| No response | 31 (15%) | 12 (8%) |
| Highest education level, n (%) | ||
| Graduate school | 3 (1.5%) | 6 (3.8%) |
| University | 84 (41.6%) | 42 (26.9%) |
| Junior college | 10 (5.1%) | 15 (9.6%) |
| Vocational school | 18 (8.7%) | 16 (10.3%) |
| High school | 50 (25.5%) | 50 (31.4%) |
| Junior high school | 11 (5.1%) | 8 (5.1%) |
| No response | 26 (13.3%) | 20 (12.8%) |
Patients’ characteristics.
*p < 0.001 (Mann–Whitney U test). IQR, interquartile range; n, number; POEM, Patient-oriented Eczema Measure; SD, standard deviation; UCT, urticaria control test.
TABLE 3
| Atopic dermatitis | Chronic spontaneous urticaria | ||||
|---|---|---|---|---|---|
| PGA | POEM ≤ 7 | POEM 8–16 | POEM ≥ 17 | UCT < 12 | UCT ≥ 12 |
| Clear or almost clear n (%) | 7 (9.5)* | 3 (5.1) | 0 (0.0)* | 8 (12.1)† | 43 (51.8)† |
| Mild n (%) | 38 (51.4)* | 16 (27.1) | 10 (20.0)* | 17 (25.8) | 34 (41.0)† |
| Moderate n (%) | 14 (18.9)* | 28 (47.5)* | 18 (36.0) | 27 (40.9)† | 2 (2.4)† |
| Severe n (%) | 4 (5.4)* | 3 (5.1)* | 15 (30.0)* | 8 (12.1)† | 0 (0.0)† |
| No answer n (%) | 11 (14.9) | 9 (15.3) | 7 (14.0) | 6 (9.1) | 4 (4.8) |
Physician global assessment and patient-reported outcomes.
p < 0.001 (Kruskal–Wallis test). †p < 0.001 Wilcoxon rank sum test. PGA, physician global assessment; POEM, Patient-oriented Eczema Measure; UCT, urticaria control test.
Opinions and concerns of patients regarding AD and CSU based on their reported outcomes
Patient age, sex, disease duration, income, willingness to undergo treatment, and ratio of those who believed that they would be cured were not related to the POEM scores. The itch NRS was associated with the POEM score (p < 0.001). Significantly more patients with low POEM scores were treated with biologics than in the other groups (p < 0.001). Patients with high POEM scores were more likely to report psychological problems (p = 0.012), difficulty with their disease (p < 0.001), and that continued treatment was necessary (p < 0.001; Table 4). Patients with high POEM scores were significantly more concerned about physical symptoms, such as itching and pain, and psychological symptoms, such as mental distress (p < 0.001). However, social factors, such as long waits for medical treatment, being unable to confide in a doctor, and concerns regarding medications were not related to the POEM scores (Table 5).
TABLE 4
| Question No | Question | ADa POEM ≤7 (n = 73) POEM 8–16 (n = 57) POEM ≥17 (n = 47) | CSUb UCT <12 (n = 65) UCT ≥12 (n = 83) |
|---|---|---|---|
| 10-1 | Continued treatment required | <0.001 | 0.022 |
| 10-2 | Things that go with us without being healed | 0.224 | 0.386 |
| 10-3 | It’s like the bad guy in a movie who doesn’t die | 0.286 | 0.01 |
| 10-4 | Related to mental state | 0.012 | 0.178 |
| 10-5 | Difficult disease | <0.001 | 0.574 |
| 10-6 | Things that get better naturally | 0.024 | 0.783 |
| 10-7 | Just like studying, things get better with effort | 0.816 | 0.337 |
Opinions of AD and CSU based on patient-reported outcomes.
Kruskal–Wallis test.
bWilcoxon rank sum test. AD, atopic dermatitis; CSU, chronic spontaneous urticaria.
TABLE 5
| Question No | Question | ADa POEM ≤7 (n = 73) POEM 8–16 (n = 57) POEM ≥17 (n = 47) | CSUb UCT <12 (n = 65) UCT ≥12 (n = 83) |
|---|---|---|---|
| 11-1 | Itchiness | <0.001 | <0.001 |
| 11-2 | Pain | <0.001 | 0.01 |
| 11-3 | Having various symptoms | <0.001 | 0.001 |
| 11-4 | Unwillingness to seek treatment | 0.048 | <0.001 |
| 11-5 | Not getting better | <0.001 | <0.001 |
| 11-6 | Repeated exacerbation and remission of symptoms over a long period of time | <0.001 | <0.001 |
| 11-7 | Few patients with the same disease | 0.026 | 0.337 |
| 11-8 | Long waiting time to see a doctor | 0.447 | 0.437 |
| 11-9 | Expensive to treat | 0.17 | 0.388 |
| 11-10 | Unknown exacerbating factors | <0.001 | 0.049 |
| 11-11 | Understanding my symptoms | <0.001 | 0.009 |
| 11-12 | Mental illness | <0.001 | <0.001 |
| 11-13 | Restriction of daily life due to illness | <0.001 | <0.001 |
| 11-14 | Not knowing how long the treatment will last | <0.001 | 0.001 |
| 11-15 | Physician failure to indicate treatment goals | 0.049 | 0.003 |
| 11-16 | Not knowing what your treatment goals are | <0.001 | 0.009 |
| 11-17 | Concerns about appearance | <0.001 | <0.001 |
| 11-18 | Not being able to tell your doctor what you want to say | 0.076 | 0.079 |
| 11-19 | Not knowing how to apply ointment | 0.052 | 0.417 |
| 11-20 | Concern about treatment with topical steroids | 0.222 | 0.932 |
| 11-21 | Concern about treatment with antihistamines (itch relievers) | 0.874 | 0.152 |
| 11-22 | Anxiety about oral cyclosporine treatment | 0.792 | 0.553 |
| 11-23 | Anxiety about treatment with biologics (Xolair, Dupixent, etc.) | 0.328 | 0.646 |
| 11-24 | Continuing treatment (without forgetting) | 0.03 | 0.422 |
Results of a significant difference test by patient-reported outcomes for each patient problem.
Kruskal–Wallis test.
bWilcoxon rank sum test.
Patients with well-controlled CSU were older (p < 0.001), had lower itch NRS scores (p < 0.001), and were more likely to believe that the disease would be cured (p < 0.001) than those with poorly controlled CSU. Sex, disease duration, income, and willingness to undergo treatment were not associated with the UCT scores. The rate of biologic treatment was significantly higher among patients with well-than poorly controlled CSU (p < 0.023). Patients in the latter group more often reported that continued treatment of CSU is necessary and that the disease was “like a movie villain who does not die easily” than those with well-controlled CSU (Table 4). Physical symptoms, such as itching and pain, and psychological symptoms, such as mental distress, were significantly more frequent in the poorly than in the well-controlled group. However, no social factors were associated with the UCT scores (Table 5).
Patients’ opinions and concerns regarding AD and CSU based on the use of biologics
Dupilumab was prescribed to 41 patients with mild AD. Patients who were treated were significantly older (p = 0.005) and had a longer disease duration (p < 0.001) and lower itch NRS scores (p < 0.001) than those who were not treated with this biologic. Opinions of AD did not significantly different between patients treated with biologics and those who were not (Table 6). Patients who were treated with biologics were less likely to report concerns regarding itching (p = 0.02), various symptoms (p = 0.008), symptoms that did not improve (p < 0.001), repeated exacerbation/remission cycles (p = 0.002), mental stress (p = 0.032), discomfort with their appearance (p = 0.006), and anxiety regarding their treatment (p < 0.001). However, the belief that few patients had the same disease and concerns regarding the cost of treatment were significantly more frequent among patients treated with biologics than those who were not (Table 7).
TABLE 6
| Question No | Question | ADa | CSUa |
|---|---|---|---|
| Dupilumab+ (n = 41) | Omalizumab+ (n = 46) | ||
| Dupilumab-(n = 142) | Omalizumab-(n = 103) | ||
| 10-1 | Continued treatment required | 0.586 | 0.924 |
| 10-2 | Things that go with us without being healed | 0.519 | 0.665 |
| 10-3 | It is like the bad guy in a movie who does not die | 0.888 | 0.012 |
| 10-4 | Related to mental state | 0.311 | 0.061 |
| 10-5 | Difficult disease | 0.577 | <0.001 |
| 10-6 | Things that get better naturally | 0.052 | 0.572 |
| 10-7 | Just like studying, things get better with effort | 0.494 | 0.569 |
Patient’s images of AD and CSU with or without biologics.
Wilcoxon rank sum test. AD, atopic dermatitis; CSU, chronic spontaneous urticaria.
TABLE 7
| Question no. | Question | ADa | CSUa |
|---|---|---|---|
| Dupilumab+ (n = 41) | Omalizumab+ (n = 46) | ||
| Dupilumab-(n = 142) | Omalizumab (n = 103) | ||
| 11-1 | Itchiness | 0.02 | 0.575 |
| 11-2 | Pain | 0.065 | 0.477 |
| 11-3 | Having various symptoms | 0.008 | 0.042 |
| 11-4 | Unwillingness to seek treatment | 0.852 | 0.235 |
| 11-5 | Not getting better | <0.001 | 0.297 |
| 11-6 | Repeated exacerbation and remission of symptoms over a long period of time | 0.002 | 0.413 |
| 11-7 | Few patients with the same disease | 0.011 | 0.002 |
| 11-8 | Long waiting time to see a doctor | 0.054 | 0.097 |
| 11-9 | Expensive to treat | <0.001 | <0.001 |
| 11-10 | Unknown exacerbating factors | 0.05 | 0.682 |
| 11-11 | Understanding my symptoms | 0.198 | 0.653 |
| 11-12 | Mental illness | 0.032 | 0.032 |
| 11-13 | Restriction of daily life due to illness | 0.433 | 0.132 |
| 11-14 | Not knowing how long the treatment will last | 0.911 | 0.813 |
| 11-15 | Physician failure to indicate treatment goals | 0.823 | 0.87 |
| 11-16 | Not knowing what your treatment goals are | 0.325 | 0.289 |
| 11-17 | Concerns about appearance | 0.006 | 0.159 |
| 11-18 | Not being able to tell your doctor what you want to say | 0.28 | 0.295 |
| 11-19 | Not knowing how to apply ointment | 0.22 | 0.864 |
| 11-20 | Concern about treatment with topical steroids | 0.62 | 0.609 |
| 11-21 | Concern about treatment with antihistamines (itch relievers) | 0.908 | 0.909 |
| 11-22 | Anxiety about oral cyclosporine treatment | 0.254 | 0.469 |
| 11-23 | Anxiety about treatment with biologics (Xolair, Dupixent, etc.) | <0.001 | <0.001 |
| 11-24 | Continuing treatment (without forgetting) | 0.731 | 0.055 |
Significant difference tests between patients with and without biologics for each problem.
Wilcoxon rank sum test.
Omalizumab was prescribed to 46 patients with CSU. Patients treated with this biologic were significantly older (p < 0.001) than those who were not. Significantly more females with CSU were prescribed omalizumab than no biologic (p = 0.035). The itch NRS score was lower (p = 0.028) among patients treated with omalizumab than among those who were not. In addition, patients treated with omalizumab were more willing to undergo treatment (p < 0.001) and more likely to believe that the disease would be cured (p = 0.001) than those who were not treated with this biologic. Patients who were treated with omalizumab were highly likely to describe CSU as “a movie villain who does not die easily” and express difficulty with the disease (Table 6). Fewer patients treated with omalizumab reported anxiety regarding the use of biologics, although more reported believing that few patients had the same disease and that they had concerns about mental distress and the cost of treatment (Table 7).
Comparison of disease effects on opinions and concerns of patients
The ANCOVA results showed that patients with CSU were significantly more willing to seek medical treatment (p = 0.035) and more likely to believe that their illness would be cured (p = 0.003) than those with AD. More patients with CSU expressed the opinion that their disease could be cured naturally than those with AD (Table 8). Physical symptoms were frequent in patients with AD. Concerns regarding exacerbating factors, ointment application, and anxiety regarding topical steroids were more prevalent among patients with CSU than those with AD (Table 9).
TABLE 8
| Question No | Question | Sum of square | Df | Mean square | F | p |
|---|---|---|---|---|---|---|
| 10-1 | Continued treatment required | 2.79 | 1 | 2.786 | 6.726 | 0.010* |
| 10-2 | Things that go with us without being healed | 26.5 | 1 | 26.453 | 24.155 | <0.001* |
| 10-3 | It is like the bad guy in a movie who does not die | 8.8 | 1 | 8.832 | 7.097 | 0.008* |
| 10-4 | Related to mental state | 10.9 | 1 | 10.904 | 11.736 | <0.001* |
| 10-5 | Difficult disease | 29.66 | 1 | 29.665 | 31.831 | <0.001* |
| 10-6 | Things that get better naturally | 15.71 | 1 | 15.708 | 20.856 | <0.001† |
| 10-7 | Just like studying, things get better with effort | 56.3 | 1 | 56.34 | 52.663 | <0.001* |
Images of AD and CSU diseases compared using ANCOVA.
Significantly higher scores in *AD, †CSU. ANCOVA, analysis of covariance; AD, atopic dermatitis; CSU, chronic spontaneous urticaria.
TABLE 9
| Question no. | Question | Sum of square | Df | Mean square | F | p |
|---|---|---|---|---|---|---|
| 11-1 | Itchiness | 4.08 | 1 | 4.078 | 4.275 | 0.040* |
| 11-2 | Pain | 33 | 1 | 33 | 24.537 | <0.001* |
| 11-3 | Having various symptoms | 22 | 1 | 22.012 | 17.965 | <0.001* |
| 11-4 | Unwillingness to seek treatment | 9.63 | 1 | 9.633 | 12.439 | <0.001* |
| 11-5 | Not getting better | 0.1 | 1 | 0.055 | 0.045 | 0.833 |
| 11-6 | Repeated exacerbation and remission of symptoms over a long period | 4.22 | 1 | 4.216 | 4.195 | 0.041* |
| 11-7 | Few patients with the same disease | 0.56 | 1 | 0.564 | 0.606 | 0.437 |
| 11-8 | Long waiting time to see a doctor | 0.39 | 1 | 0.388 | 0.387 | 0.534 |
| 11-9 | Expensive to treat | 3.9 | 1 | 3.941 | 3.441 | 0.065 |
| 11-10 | Unknown exacerbating factors | 4.96 | 1 | 4.959 | 5.099 | 0.025† |
| 11-11 | Understanding my symptoms | 1.27 | 1 | 1.271 | 1.433 | 0.232 |
| 11-12 | Mental illness | 2.6 | 1 | 2.609 | 2.356 | 0.126 |
| 11-13 | Restriction of daily life due to illness | 7.7 | 1 | 7.708 | 6.019 | 0.015* |
| 11-14 | Not knowing how long the treatment will last | 0.5 | 1 | 0.45 | 0.429 | 0.513 |
| 11-15 | Physician failure to indicate treatment goals | 1.05 | 1 | 1.051 | 1.262 | 0.262 |
| 11-16 | Not knowing what your treatment goals are | 0.7 | 1 | 0.699 | 0.605 | 0.437 |
| 11-17 | Concerns about appearance | 49.4 | 1 | 49.39 | 40.67 | <0.001* |
| 11-18 | Not being able to tell your doctor what you want to say | 1.55 | 1 | 1.554 | 2.54 | 0.112 |
| 11-19 | Not knowing how to apply ointment | 9.2 | 1 | 9.25 | 6.556 | 0.011† |
| 11-20 | Concern about treatment with topical steroids | 10.4 | 1 | 10.365 | 4.946 | 0.027† |
| 11-21 | Concern about treatment with antihistamines (itch relievers) | 14.8 | 1 | 14.83 | 8.596 | 0.004* |
| 11-22 | Anxiety about oral cyclosporine treatment | 0.5 | 1 | 0.47 | 0.131 | 0.718 |
| 11-23 | Anxiety about treatment with biologics (Xolair, Dupixent, etc.) | 8.5 | 1 | 8.496 | 2.362 | 0.125 |
| 11-24 | Continuing treatment (without forgetting) | 13.1 | 1 | 13.096 | 12.526 | <0.001* |
Results of multivariate analysis comparing the difficulties of AD and CSU.
Significantly higher scores in *AD and †CSU.
Discussion
Patients’ images of disease are currently being investigated as narrative-based medicine [11]. In addition, since medication compliance increases with treatment satisfaction, images of a disease might also be associated with compliance [12]. The opinions of patients about diseases have been investigated in the fields of psychiatry [1] and diabetes [13]. By contrast, information about such opinions, particularly about allergic diseases, is scant in the field of dermatology. Therefore, our findings contain valuable information. Medication compliance is essential to effectively treat AD and CSU. Increasing patient satisfaction with treatment and their realization of the beneficial effects of drugs improve their compliance [12, 14], as we showed herein. We also found that patients who applied biologics reported fewer symptoms, although the cost of treatment was a concern. These findings suggested that the high cost of biologics forces patients to choose between paying for treatment or experiencing symptoms. In addition, fewer patients described anxiety regarding the application of biologics. The severity of AD and treatment satisfaction correlated in a study that assessed patients using the Treatment Satisfaction Questionnaire for Medication [15]. Reducing disease severity increases patient satisfaction and adherence to treatment regimens, creating a cycle that results in sufficient therapeutic effects.
Psychosocial effects (such as isolation, sociability, stigma, effects of illness on activity, and hopelessness) and noncompliance can be used to identify patients with psoriasis who require additional support to overcome issues with treatment compliance [16]. We did not identify any correlations between the opinions and concerns of patients regarding AD or CSU. Disease severity often correlates with the opinions and concerns of patients, as the present study also found. These findings highlight the importance of relieving symptoms to improve patient opinions of the disease. We evaluated viewpoints and concerns before and after treatment with biologics in a small subset of patients (data not shown). Although the subset was small, the findings suggested that symptomatic relief owing to treatment improved the opinions and reduced the concerns of patients regarding their disease.
That mental illness also correlates with severity is a notable concern (Table 5), and psychosomatic therapy is important in treating allergic diseases. However, not many allergists practice psychosomatic therapy. Allergic diseases associated with psychosomatic disorders are often severe or refractory to treatment with a conventional bio-medical model. A psychosomatic diagnosis and treatment are necessary according to the psycho-socio-eco-medical model of disease understanding [17].
Atopic dermatitis is an inflammatory skin disease that affects over 1 in 10 children in Japan [6]. Although it is believed that AD remits with age, epidemiological studies have found that AD follows a lifelong episodic course when it presents after the age of 12 years [18, 19]. A gradual change in treatment expectations from cure to control is associated with a long-term acceptance of AD and a hope of being cured [5]. By increasing awareness regarding the long-term nature of eczema among adolescents, effective self-care habits can be encouraged [5]. Our patients did not report the belief that AD improves naturally, which might be because adults with AD were included in the study and AD often cannot be cured if it presents in adulthood. By contrast, patients were more likely to report the belief that CSU naturally improves, which corresponded to the median duration of CSU being 4 years.
The viewpoints and concerns of the patients were subjectively evaluated. Therefore, a comparator was included to increase understanding of the significance of our findings. Therefore, we compared the viewpoints and concerns of patients with AD and CSU using a multivariate analysis. More patients with CSU reported that the symptoms naturally improves, as eruptions appear and disappear. Many patients agreed that the image of disease presented in the other questions applied to AD. More patients with AD reported concerns regarding their physical and mental symptoms than those with CSU. Patients with AD reported concerns regarding antihistamines, which lead to less noticeable effects in patients with AD than in those with CSU. In addition, patients with CSU reported concerns regarding topical drugs, which are not recommended in international [9] or Japanese [7] guidelines. These guidelines must be adhered to in clinical practice.
This study is not without limitations. Patients who responded to the questionnaire were seen by dermatologists and allergists at hospitals offering relatively innovative care. This could have affected the range of treatment choices. All our patients were old enough to answer questions, which might have introduced bias. Simple comparisons between AD and CSU were difficult because of differences in mean disease activity, so analysis of covariance (ANCOVA) was performed to compare the two diseases.
In conclusion, patients’ opinions and concerns differ based on specific diseases. Patients’ opinions are influenced by disease severity and types of treatment. Patients were concerned about ineffective treatment. Understanding these characteristics can be used to improve patient satisfaction and compliance, ultimately resulting in favorable outcomes.
Statements
Data Availability Statement
The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.
Ethics Statement
This study was approved by the ethics committees and Deans of the Faculty of Medicine of Shimane University (approval no. 4418), Masuda RedCross Hospital (approval no. 80), Kyushu University (approval no. 2020-327), SUMIKAWA Dermatology and Allergy Clinic (approval no. 20200717), Kobe University (approval no. B200149), Kyoto Prefectural University (approval no. ERB-C-1828-1), and Fukushima Medical University School of Medicine (approval no. 2020-101). This study proceeded according to the Declaration of Helsinki (2013 amendment). All patients provided written, informed consent to participate in this study.
Author Contributions
All authors participated in the design, interpretation of the studies and analysis of the data and review of the manuscript; SK, TN, YS, AF and KM conducted the questionnaire, TK analyzed the questionnaire. All authors wrote the manuscript.
Funding
This study was partially supported by Collaborative Research Grants 2020–2022 from the Japanese Society for Cutaneous Immunology and Allergy.
Acknowledgments
We thank the clerk in the Masuda RedCross Hospital for assisting with this study. We also thank Editage (www.editage.com) for English language editing.
Conflict of Interest
SK has received an honorarium as a speaker from Ely-Lilly Japan and Abbvie. TN has received an honorarium as a speaker from Sanofi, Maruho, Ely-Lilly Japan and Abbvie. YS has received fees as a speaker from Sanofi, Maruho, Ely-Lilly Japan and Abbvie. AF has received fees as a speaker from Sanofi, Maruho, Ely-Lilly Japan, Abbvie, Torii, Novartis, Taiho, Tanabe-Mitsubishi and fees for funded research/joint research from Taiho. KM has received honoraria as a speaker for Sanofi and grants as an investigator for Eli Lilly Japan.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
Cleary SD Bhatty S Broussard B Cristofaro SL Wan CR Compton MT . Measuring insight through patient self-report: an in-depth analysis of the factor structure of the Birchwood Insight Scale. Psychiatry Res (2014) 216:263–8. 10.1016/j.psychres.2014.01.043
2
Drucker AM Wang AR Li WQ Sevetson E Block JK Qureshi AA . The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol (2017) 137:26–30. 10.1016/j.jid.2016.07.012
3
Nakahara T Fujita H Arima K Taguchi Y Motoyama S Furue M . Perception gap between patients and physicians regarding disease burden and treatment satisfaction in atopic dermatitis: findings from an on-line survey. Jpn J Dermatol (2018) 128:2843–55. In Japanese.
4
Kaneko S Masuda K Hiragun T Inomata N Furue M Onozuka D et al Transient improvement of urticaria induces poor adherence as assessed by Morisky Medication Adherence Scale-8. J Dermatol (2015) 42:1078–82. 10.1111/1346-8138.12971
5
Ghio D Muller I Greenwell K Roberts A McNiven A Langan SM et al ‘It’s like the bad guy in a movie who just doesn’t die’: a qualitative exploration of young people’s adaptation to eczema and implications for self-care. Br J Dermatol (2020) 182:112–8. 10.1111/bjd.18046
6
Katoh N Ohya Y Ikeda M Ebihara T Katayama I Saeki H et al Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol (2019) 46:1053–101. 10.1111/1346-8138.15090
7
Hide M . Japanese guidelines for diagnosis and treatment of urticaria 2018. Arerugi (2018) 67:1394–8. 10.15036/arerugi.67.1394
8
Charman CR Venn AJ Williams HC . The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol (2004) 140:1513–9. 10.1001/archderm.140.12.1513
9
Zuberbier T Aberer W Asero R Abdul Latiff AH Baker D Ballmer-Weber B et al The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy (2018) 73:1393–414. 10.1111/all.13397
10
R Development Core Team. R: a language and environment for statistical 385 computing. Vienna, Austria: R Foundation for Statistical Computing (2016).
11
Fioretti C Mazzocco K Riva S Oliveri S Masiero M Pravettoni G . Research studies on patients’ illness experience using the narrative medicine approach: a systematic review. BMJ Open (2016) 6:e011220. 10.1136/bmjopen-2016-011220
12
Furue M Onozuka D Takeuchi S Murota H Sugaya M Masuda K et al Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8. Br J Dermatol (2015) 172:272–5. 10.1111/bjd.13377
13
Rozenfeld Y Hunt JS Plauschinat C Wong KS . Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care (2008) 14:71–5.
14
Murota H Takeuchi S Sugaya M Tanioka M Onozuka D Hagihara A et al Characterization of socioeconomic status of Japanese patients with atopic dermatitis showing poor medical adherence and reasons for drug discontinuation. J Dermatol Sci (2015) 79:279–87. 10.1016/j.jdermsci.2015.05.010
15
Nakahara T Fujita H Arima K Taguchi Y Motoyama S Furue M . Treatment satisfaction in atopic dermatitis relates to patient‐reported severity: a cross‐sectional study. Allergy (2019) 74:1179–81. 10.1111/all.13712
16
Bewley A Burrage DM Ersser SJ Hansen M Ward C . Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. J Eur Acad Dermatol Venereol (2014) 28:763–70. 10.1111/jdv.12174
17
Ago Y . Psychosomatic treatment of allergic disorders. Arerugi (2001) 50:5–10.
18
Abuabara K Yu AM Okhovat JP Allen IE Langan SM . The prevalence of atopic dermatitis beyond childhood: a systematic review and meta-analysis of longitudinal studies. Allergy (2018) 73:696–704. 10.1111/all.13320
19
Roduit C Frei R Depner M Karvonen AM Renz H Braun-Fahrländer C et al Phenotypes of atopic dermatitis depending on the timing of onset and progression in childhood. JAMA Pediatr (2017) 171:655–62. 10.1001/jamapediatrics.2017.0556
Summary
Keywords
patient perspective, atopic dermatitis, chronic spontaneous urticaria, cross-sectional survey, Japan
Citation
Kaneko S, Nakahara T, Sumikawa Y, Fukunaga A, Masuda K and Kakamu T (2024) Disease perception in patients with atopic dermatitis and chronic spontaneous urticaria: a cross-sectional survey in Japan. J. Cutan. Immunol. Allergy 7:12476. doi: 10.3389/jcia.2024.12476
Received
27 November 2023
Accepted
30 January 2024
Published
14 February 2024
Volume
7 - 2024
Updates
Copyright
© 2024 Kaneko, Nakahara, Sumikawa, Fukunaga, Masuda and Kakamu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Sakae Kaneko, kanekos3@masuda.jrc.or.jp
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.